Patents Assigned to University Health Network
  • Patent number: 11662315
    Abstract: A method and device for determining the depth and fluorophore concentration of a fluorophore concentration below the surface of an optically absorbing and scattering medium suitable for use in fluorescence-based surgical guidance such as in tumor resection is described. Long-wavelength stimulus light us used to obtain deep tissue penetration. Recovery of depth is performed by fitting measured modulation amplitudes for each spatial frequency to precomputed modulation amplitudes in a table of modulation amplitudes indexed by optical parameters and depth.
    Type: Grant
    Filed: November 1, 2021
    Date of Patent: May 30, 2023
    Assignees: THE TRUSTEES OF DARTMOUTH COLLEGE, UNIVERSITY HEALTH NETWORK
    Inventors: Keith D. Paulsen, David W. Roberts, Dennis Wirth, Brian C. Wilson, Mira Sibai
  • Publication number: 20230148588
    Abstract: An organ perfusion solution includes a colloid component, a salt mixture, a buffer system, and a glutamine compound in a physiologically acceptable medium.
    Type: Application
    Filed: March 26, 2021
    Publication date: May 18, 2023
    Applicant: University Health Network
    Inventors: Mingyao LIU, Shafique KESHAVJEE
  • Publication number: 20230128394
    Abstract: There is provided herein a method for expanding human CD4?CD8? regulatory T cells (DN Tregs) from a population of cells comprising DN Tregs, comprising: culturing the population of cells with artificial antigen presenting cells (APCs), preferably the DN Tregs are ??-TCR+CD56? or alternatively ??-TCR+.
    Type: Application
    Filed: December 23, 2022
    Publication date: April 27, 2023
    Applicant: UNIVERSITY HEALTH NETWORK
    Inventors: Li ZHANG, Paulina ACHITA, Jongbok LEE, Dalam LY, Dzana DERVOVIC
  • Patent number: 11636288
    Abstract: Embodiments described herein provide a platform, device and process for digital pathology that enable multi-level annotation and visualization of histopathologic slides using a modular arrangement of deep convolutional neural networks (CNNs). The CNNs can be trained using pathology images (e.g., in some cases increasing the base of data by breaking larger fields of view into smaller ones) to learn features consistent with certain pathologies. The platform can use the CNNs to visually annotate pathology slides at an interface tool of a display device. The platform can automate the process of selection, as well as provide an opportunity for the pathologist to see a depiction of predicted results. The platform can use the CNNs to identify regions of interest on pathology slides. The interface tool can enable a predicted region of interest (ROI) type to be visually presented on a surface map showing the basis of the prediction.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: April 25, 2023
    Assignee: UNIVERSITY HEALTH NETWORK
    Inventors: Kevin Faust, Zoya Volynskaya, Ugljesa Djuric, Phedias Diamandis
  • Patent number: 11629185
    Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: April 18, 2023
    Assignees: NOVO NORDISK A/S, UNIVERSITY HEALTH NETWORK
    Inventors: Tarlochan S. Nijjar, Avijit Chakrabartty, Jeffrey N. Higaki
  • Patent number: 11607454
    Abstract: Devices, materials, compounds, systems, and processes for Cherenkov-Activated Nuclear-Targeted Photodynamic Therapy that involves generating Cherenkov light within the tissue of a target volume and using this light to activate photosensitizing material that is located in the nucleus of cells of the target volume.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: March 21, 2023
    Assignee: UNIVERSITY HEALTH NETWORK
    Inventors: Brian Wilson, Christine Allen
  • Patent number: 11597917
    Abstract: The present invention is related to a dual promoter lentiviral vector and methods of use for the treatment of diseases and disorders, specifically lysosomal storage disorders.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: March 7, 2023
    Assignees: The Medical College of Wisconsin, Inc., University Health Network, Washington University in St. Louis
    Inventors: Jeffrey A. Medin, John F. Dipersio, Murtaza S. Nagree
  • Patent number: 11572354
    Abstract: Inhibition of indoleamine 2,3-dioxygenase (IDO1) is an attractive immunotherapeutic approach for the treatment of a variety of cancers. Dysregulation of this enzyme has also been implicated in other severe diseases such as Alzheimer's disease and arthritis. Small molecule inhibitors of Formula (Ia) and (Ib) of IDO, their synthesis, and uses thereof are provided.
    Type: Grant
    Filed: January 9, 2019
    Date of Patent: February 7, 2023
    Assignee: University Health Network
    Inventors: Donald Weaver, Michael G. Brant, Stephanie Wohnig, Fan Wu, Jake Goodwin-Tindall, Autumn Meek, Paolo Schiavini
  • Patent number: 11560558
    Abstract: There is described herein, a method of capturing cell-free methylated DNA from a sample having less than 100 mg of cell-free DNA, comprising the steps of: subjecting the sample to library preparation to permit subsequent sequencing of the cell-free methylated DNA; adding a first amount of filler DNA to the sample, wherein at least a portion of the filler DNA is methylated; denaturing the sample; and capturing cell-free methylated DNA using a binder selective for methylated polynucleotides.
    Type: Grant
    Filed: November 4, 2021
    Date of Patent: January 24, 2023
    Assignees: UNIVERSITY HEALTH NETWORK, SINAI HEALTH SYSTEM
    Inventors: Daniel Diniz De Carvalho, Shu Yi Shen, Rajat Singhania
  • Patent number: 11547725
    Abstract: There is described herein, a method for inducing Tc22 lineage T cells from a population of CD8+ T cells, the method comprising: a) providing a population of CD8+ T cells; b) activating the population; and c) culturing or contacting the population of CD8+ T cells with Coenzyme A.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: January 10, 2023
    Assignee: UNIVERSITY HEALTH NETWORK
    Inventors: Pamela S. Ohashi, Michael St. Paul, Sam Saibil
  • Publication number: 20230000356
    Abstract: A system for outputting a representation of a wound in tissue comprises a housing configured to removably receive at least a portion of a wireless communication device. At least one light source coupled to the housing is configured to emit excitation light to illuminate a target which includes at least a portion of the wound. A power supply contained in the housing is configured to provide power to the light source. A non-transitory computer-readable medium stores a program executable to cause the performance of operations comprising detecting signals responsive to illumination of the target, outputting the representation of the target based thereon, storing data relative to one or more target surface parameter based on the detected signals, and displaying the representation. The signals correspond to at least one of endogenous or exogeneous fluorescence, absorbance, and reflectance from at least one biological component in and/or on the target.
    Type: Application
    Filed: July 1, 2022
    Publication date: January 5, 2023
    Applicant: UNIVERSITY HEALTH NETWORK
    Inventors: Ralph Sebastian Dacosta, Brian C. Wilson, Kai Zhang
  • Patent number: 11534460
    Abstract: There is provided herein a method for expanding human CD4-CD8- regulatory T cells (DN Tregs) from a population of cells comprising DN Tregs, comprising: culturing the population of cells with artificial antigen presenting cells (APCs), preferably the DN Tregs are ??-TCR-CD56- or alternatively ?8-TCR+.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: December 27, 2022
    Assignee: University Health Network
    Inventors: Li Zhang, Paulina Achita, Jong Lee, Dalam Ly, Dzana Dervovic
  • Patent number: 11504075
    Abstract: Uptake of hypoxia-sensitive PET tracers is dependent on tissue transport properties, specifically, distribution volume. Variability in tissue transport properties reduces the sensitivity of static PET imaging to hypoxia. When tissue transport (vd) effects are substantial, correlations between the two methods of determining hypoxic fractions are greatly reduced—that is, trapping rates k3 are only modestly correlated with tumour-to-blood ratio (TBR). In other words, the usefulness of dynamic- and static-PET based hypoxia surrogates, trapping rate k3 and TBR, in determining hypoxic fractions is reduced in regions where diffusive equilibrium is achieved slowly. A process is provided for quantifying hypoxic fractions using a novel biomarker for hypoxia, hypoxia-sensitive tracer binding rate kb, based on PET imaging data. The same formalism can be applied to model the kinetics of non-binding CT and MT contrast agents, giving histopathological information about the imaged tissue.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: November 22, 2022
    Assignee: UNIVERSITY HEALTH NETWORK
    Inventors: Edward Taylor, David A. Jaffray, Ivan Wai Tong Yeung
  • Patent number: 11499195
    Abstract: There is described herein a method of prognosing and/or predicting disease progression and/or in subject with prostate cancer, the method comprising: a) providing a sample containing mitochondrial genetic material from prostate cancer cells; b) sequencing the mitochondrial genetic material with respect to at least 1 patient biomarker selected from CSB1, OHR, ATP8 and HV1 (hypervariable region 1); c) comparing the sequence of the patient biomarkers to control or reference biomarkers to determine mitochondrial single nucleotide variations (mtSNVs); and d) determining the a prostate cancer prognosis; wherein a relatively worse outcome is associated with the presence of mtSNVs in CSB1, OHR, ATP8 and a relatively better outcome is associated with the presence of mtSNVs in HV1.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: November 15, 2022
    Assignees: Ontario Institute for Cancer Research, University Health Network
    Inventors: Julia A. Hopkins, Paul Boutros, Robert G. Bristow
  • Patent number: 11497796
    Abstract: Disclosed herein is an agent that modulates a cis interaction between Repulsive Guidance Molecule A (RGMa) and Neogenin or lipid rafts. Modulation by the agent may include blocking the cis interaction between RGMa and Neogenin and/or disrupting lipid rafts. In turn, this promotes neuronal cell survival and axon growth and/or regeneration. Also disclosed herein is a method of treating a disease in a subject in need thereof. The method may include administering the agent to the subject. Further disclosed herein is a method of identifying an agent that modulates the cis interaction between RGMa and Neogenin.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: November 15, 2022
    Assignee: UNIVERSITY HEALTH NETWORK
    Inventors: Philippe P. Monnier, Nardos G. Tassew
  • Patent number: 11491180
    Abstract: There is disclosed herein compositions, methods, uses and systems for reducing pain in a patient that emanates from a body area, preferably spine or joint. Methods of treatment or prevention are described for a disease or condition selected from degenerative disc disease, disc injury, pain, arthritis, or suspected arthritis.
    Type: Grant
    Filed: June 25, 2021
    Date of Patent: November 8, 2022
    Assignees: UNIVERSITY HEALTH NETWORK, NOTOGEN. INC.
    Inventors: William Mark Erwin, Bjorn C. J. Eek
  • Patent number: 11485057
    Abstract: The present invention provides a method of producing the composite comprising: a) melt blending the matrix with the fibers to produce a melted composite, b) injecting the melted composite into a mold and allowing the melted composite to solidify and, c) removing at least a portion of the outermost layer of a composite such that the fibers protrude from the surface of the composite. Also provided is composite produced by the methods of the invention comprising soft and hard fibers embedded in a soft rubber-like matrix, wherein the fibers protrude from the composite's surface. In specific embodiments, the composite comprises carbon fibers and poly(p-phenylene-2,6-benzobisoxazole) (PBO) fibers in a thermoplastic polyurethane (TPU) matrix, wherein the fibers protrude from the composite's surface. Slip-resistant product comprising the composite are also provided.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: November 1, 2022
    Assignee: University Health Network
    Inventors: Zahra S. Bagheri, Ali O. Anwer, Reza Rizvi, Hani E. Naguib, Tilak Dutta, Geoffrey Roy Fernie
  • Patent number: 11471480
    Abstract: There is disclosed herein compositions, methods, uses and systems for reducing pain in a patient that emanates from a body area, preferably spine or joint. Methods of treatment or prevention are described for a disease or condition selected from degenerative disc disease, disc injury, pain, arthritis, or suspected arthritis.
    Type: Grant
    Filed: June 25, 2021
    Date of Patent: October 18, 2022
    Assignees: UNIVERSITY HEALTH NETWORK, NOTOGEN, INC.
    Inventors: William Mark Erwin, Bjorn C. J. Eek
  • Publication number: 20220324938
    Abstract: The present disclosure is directed recombinant T cell receptors capable of binding a tyrosinase epitope, a MAGA-A1 epitope, a MART1 epitope, a MAGE-A3 epitope, or an SSX2 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.
    Type: Application
    Filed: March 24, 2020
    Publication date: October 13, 2022
    Applicant: University Health Network
    Inventors: Naoto HIRANO, Kenji MURATA, Kayoko SASO
  • Publication number: 20220291215
    Abstract: The present disclosure is directed to methods of identifying MHC class II-specific T cell receptors (TCRs). In certain aspects, the method comprises contacting a T cell with a complex comprising an (i) MHC class II molecule having a higher affinity for CD4 than naturally occurring MHC class II molecules and (ii) a peptide, e.g., an epitope. In certain aspects, the HLA class II molecule comprises a beta chain having one or more mutations relative to a wild-type beta chain sequence.
    Type: Application
    Filed: July 29, 2020
    Publication date: September 15, 2022
    Applicant: University Health Network
    Inventors: Naoto HIRANO, Munehide NAKATSUGAWA, Yuki YAMASHITA, Kenji SUGATA, Muhammed Aashiq RAHMAN